TCGA-AN-A0FV-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 0
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- MTORC1_SIGNALING+0.310
- ANGIOGENESIS+0.300
- GLYCOLYSIS+0.260
- CHOLESTEROL_HOMEOSTASIS+0.250
- PROTEIN_SECRETION+0.240
- MYOGENESIS+0.230
- SPERMATOGENESIS+0.230
- HEDGEHOG_SIGNALING+0.220
- APICAL_JUNCTION+0.210
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.520
- IL6_JAK_STAT3_SIGNALING-0.440
- INTERFERON_GAMMA_RESPONSE-0.400
- INFLAMMATORY_RESPONSE-0.370
- INTERFERON_ALPHA_RESPONSE-0.370
- TNFA_SIGNALING_VIA_NFKB-0.350
- WNT_BETA_CATENIN_SIGNALING-0.230
- IL2_STAT5_SIGNALING-0.190
- ESTROGEN_RESPONSE_EARLY-0.180
- APOPTOSIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HY-01A-11R-A056-07 | — | C | 0.790 |
| 2 | 034df4c4-52bd-4025-aee4-ad630d0d00af | — | — | 0.772 |
| 3 | s0095123 | — | — | 0.767 |
| 4 | 48155bad-7de9-401d-a495-972cbbb8f276 | — | — | 0.763 |
| 5 | SRR8518245 | — | F | 0.751 |
| 6 | SRR5088861 | — | — | 0.730 |
| 7 | SRR8518380 | — | C | 0.729 |
| 8 | SRR25617914 | — | C | 0.728 |
| 9 | BSR_19_0079_A1_S53 | — | B | 0.728 |
| 10 | SRR8518158 | — | E | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |